Skip to main content

Psoriatic arthritis

      Shifting Treatment Paradigms in Psoriatic Arthritis: Dr. Eric Ruderman

      Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at ACR 2020.

      RT @MeralElRamahiMD: So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheu
      So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
      RT @_connectedcare: This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis 💪

      T
      This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis 💪 Take your time. The top half looks at joint efficacy. The bottom half for skin efficacy. #ACR20 https://t.co/FXhJunXNKt
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by Rhe
      4 years ago
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.
      RT @doctorRBC: EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
      1️⃣Clinical resolution of enthesi
      EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts 1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC 2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC @RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
      PsA Studies: Entheses, Ultrasound, Swollen not Tender Joints: Dr. Antoni Chan

       

      Dr. Antoni Chan reviews three PsA studies - abstracts #0311, #0315 and #0313 - presented Friday at the 2020 ACR annual meeting.

      RT @uptoTate: Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentia
      Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells. Phase II trial shows efficacy in PsA, further trials to come. #ABS0894 #ACR20 @RheumNow https://t.co/gzf7epPyNd https://t.co/ArLlCyzLxR
      RT @uptoTate: Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect
      Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0